NanoViricides, Inc. (NYSE American: NNVC) announced that a Phase II clinical trial of its antiviral candidate NV-387 for the treatment of MPox is expected to begin soon in the Democratic Republic of Congo, with site preparation and staff training scheduled for early April 2026. The study, already approved by the DRC regulatory agency, will evaluate the safety and effectiveness of NV-387 against Clade I MPox, as the company advances regulatory development and seeks Orphan Drug Designation from the U.S. FDA.
This trial marks a significant step for NanoViricides as it moves its lead drug candidate into later-stage clinical testing. NV-387 is a broad-spectrum antiviral drug that the company plans to develop for multiple viral infections, including respiratory syncytial virus (RSV), COVID-19, Long COVID, influenza, and MPox/smallpox infections. The company believes that NV-387's unique mechanism, based on its nanoviricide technology, could offer a novel approach to treating viral diseases that are often resistant to conventional therapies.
The Democratic Republic of Congo was chosen for this trial due to the high prevalence of Clade I MPox, which is considered more severe than the Clade II strain that caused the global outbreak in 2022. By conducting the trial in an endemic region, NanoViricides aims to demonstrate the drug's effectiveness in a real-world setting where the virus is actively circulating. The company has also secured regulatory approval from the DRC's health authorities, expediting the trial's initiation.
In parallel, NanoViricides is seeking Orphan Drug Designation from the U.S. FDA, which would provide incentives such as tax credits and market exclusivity upon approval. This designation is typically granted to drugs that treat rare diseases affecting fewer than 200,000 people in the United States. While MPox is not common in the U.S., the potential for bioterrorism or future outbreaks makes the development of effective treatments a public health priority.
NanoViricides' platform technology, based on TheraCour nanomedicine, involves designing nanomaterials that mimic host cell receptors to bind and neutralize viruses. The company has a broad pipeline of drug candidates targeting various viral diseases, including HIV, hepatitis B and C, rabies, herpes, influenza, dengue, and Ebola. However, the company acknowledges the risks inherent in drug development, noting that there can be no assurance that any of its candidates will prove effective or safe in clinical trials.
The Phase II trial's initiation is a critical milestone for NanoViricides, which has been focusing on advancing NV-387 into human trials. The company's business model relies on licensing technology from TheraCour Pharma, Inc., and it holds exclusive licenses for several antiviral applications. As the trial progresses, investors and public health officials will be watching closely for data on NV-387's safety and efficacy against Clade I MPox, which could pave the way for regulatory submissions and potential commercialization.
For more information, visit the company's newsroom at https://ibn.fm/NNVC and the full press release at https://ibn.fm/4Ckhk.
